Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Waubant, D. Goodkin, L. Gee, P. Bacchetti, R. Sloan, T. Stewart, P. Andersson, G. Stabler, K. Miller (1999)
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.Neurology, 53 7
V. Wee, Yong, Wee Yong (2002)
Differential mechanisms of action of interferon-β and glatiramer acetate in MSNeurology, 59
A. Hajifathali, A. Sayad, A. Sayad, A. Sayad, Z. Arjang, Y. Mohseni, Golamreza Babamohammadi, S. Zare, Ali Sarzaeem, A. Akbari, Nooshin Asgari (2012)
The association of -308 TNFα polymorphism and multiple sclerosis in Iranian patientsJournal of Biology and Today`s World, 1
A. Chambers, L. Matrisian (1997)
Changing views of the role of matrix metalloproteinases in metastasis.Journal of the National Cancer Institute, 89 17
A. Lukes, S. Mun-Bryce, Manuela Lukes, G. Rosenberg (1999)
Extracellular matrix degradation by metalloproteinases and central nervous system diseasesMolecular Neurobiology, 19
E. Lewis, J. Bishop, K. Bottomley, D. Bradshaw, M. Brewster, M. Broadhurst, P. Brown, J. Budd, L. Elliott, A. Greenham, W. Johnson, J. Nixon, F. Rose, B. Sutton, K. Wilson (1997)
Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivoBritish Journal of Pharmacology, 121
V. Yong, C. Power, P. Forsyth, D. Edwards (2001)
Metalloproteinases in biology and pathology of the nervous systemNature Reviews. Neuroscience, 2
M. Ram, Y. Sherer, Y. Shoenfeld (2006)
Matrix Metalloproteinase-9 and Autoimmune DiseasesJournal of Clinical Immunology, 26
S. Izadi, A. Nikseresht, M. Sharifian, M. Sahraian, A. Jahromi, M. Aghighi, A. Heidary (2014)
Significant Increase in the Prevalence of Multiple Sclerosis in Iran in 2011Iranian Journal of Medical Sciences, 39
B. Dubois, G. Opdenakker, H. Carton (1999)
Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis.Acta neurologica Belgica, 99 1
W. Stetler-Stevenson (1999)
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.The Journal of clinical investigation, 103 9
M. Mazdeh, M. Taheri, A. Sayad, S. Bahram, M. Omrani, A. Movafagh, H. Inoko, M. Akbari, R. Noroozi, M. Hajilooi, G. Solgi (2016)
HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.Pharmacogenomics, 17 5
R. Karabudak, A. Kurne, D. Guc, M. Şengelen, H. Canpınar, E. Kansu (2004)
Effect of interferon β-1a on serum matrix metalloproteinase—9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patientsJournal of Neurology, 251
D. Leppert, E. Waubant, M. Bürk, J. Oksenberg, S. Hauser (1996)
Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosisAnnals of Neurology, 40
M. Egeblad, Z. Werb (2002)
New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2
W. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. Hartung, F. Lublin, H. McFarland, D. Paty, C. Polman, S. Reingold, M. Sandberg-wollheim, W. Sibley, A. Thompson, S. Noort, B. Weinshenker, J. Wolinsky (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 50
M. Lee, J. Palace, G. Stabler, J. Ford, Andrew Gearing, K. Miller (1999)
Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.Brain : a journal of neurology, 122 ( Pt 2)
P. Burrage, K. Mix, C. Brinckerhoff (2006)
Matrix metalloproteinases: role in arthritis.Frontiers in bioscience : a journal and virtual library, 11
K. Gijbels, S. Masure, H. Carton, G. Opdenakker (1992)
Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disordersJournal of Neuroimmunology, 41
A. Sayad, A. Allameh, A. Sayad, M. Noruzinia, M. Akbari, Ali Sarzaeem, A. Akbar, Reza Hoseini (2013)
The Association of -475 and -631 Interleukin-2 Gene Polymorphism with Multiple Sclerosis in Iranian PatientsCell Journal (Yakhteh), 15
Á. Alonso, M. Hernán (2008)
Temporal trends in the incidence of multiple sclerosisNeurology, 71
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky (2011)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 69
A. Sayad, A. Allameh, M. Noruzinia (2013)
THE INFLUENCE OF -330 IL-2 GENE POLYMORPHISM ON RELAPSING REMITTING AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN IRANIAN PATIENTS, 18
J. Sastre-Garriga, M. Comabella, L. Brieva, À. Rovira, M. Tintoré, X. Montalban (2004)
Decreased MMP-9 production in primary progressive multiple sclerosis patientsMultiple Sclerosis, 10
M. Taheri, Shirin Nemati, A. Movafagh, M. Saberi, R. Mirfakhraie, M. Eftekharian, S. Arsang-Jang, Amir Rezagholizadeh, A. Sayad (2016)
TRAIL gene expression analysis in multiple sclerosis patients.Human antibodies, 24 1-2
M. Yushchenko, F. Weber, M. Mäder, U. Schöll, M. Maliszewska, H. Tumani, K. Felgenhauer, W. Beuche (2000)
Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell countJournal of Neuroimmunology, 110
K. Berer, G. Krishnamoorthy (2014)
Microbial view of central nervous system autoimmunityFEBS Letters, 588
R. Milo, E. Kahana (2010)
Multiple sclerosis: geoepidemiology, genetics and the environment.Autoimmunity reviews, 9 5
A. Sayad (2014)
The association of −330 interleukin‐2 gene polymorphism and HLA‐DR15 allele in Iranian patients with multiple sclerosisInternational Journal of Immunogenetics, 41
G. Rosenberg (2002)
Matrix Metalloproteinases and Neuroinflammation in Multiple SclerosisThe Neuroscientist, 8
C. Avolio, M. Ruggieri, F. Giuliani, G. Liuzzi, R. Leante, P. Riccio, P. Livrea, M. Trojano (2003)
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypesJournal of Neuroimmunology, 136
E. Waubant, D. Goodkin, A. Bostrom, P. Bacchetti, J. Hietpas, R. Lindberg, D. Leppert (2003)
IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMSNeurology, 60
BACKGROUND: Multiple sclerosis (MS) is an inflammatory,immune-mediated, demyelinating disease of the central nervous system whichdisturbs cerebral vascular permeability.OBJECTIVE: Matrix metalloproteinase can increase capillarypermeability and are involved in neurological diseases.METHODS: The study compared the expression level of MMP9 gene inRRMS samples with normal individuals in Iran. RNA from the buffy coat of 50RRMS patients and 50 normal controls were extracted. All patients wereHLA-DRB1*15 negative and were responders to interferon-beta with a normalvitamin D level. The level of MMP9 gene expression was measured usingquantitative RT-PCR.RESULTS: The RRMS patients manifested a higher expression level ofMMP9 than their normal counterparts (P= 0.02). Age-wise, there was nocorrelation between different age groups (> 30, 30-40, 40 <). In terms of sex,only the female patients manifested a statistically significant increase inMMP9 (p value = 0.037). Besides, there was no linear correlation between MMP9expression level and risk of Expanded Disability Status Scale ofKurtzke (EDSS); nor were there any significant correlation betweenexpression status of MMP9 and duration of the disease.CONCLUSION: Up regulation of MMP9 gene expression would happen in RRMS IFN-B responders,but the level of increase in female patients is significantly more thanmales.
Human Antibodies – IOS Press
Published: Jan 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.